HopeStage
Back to all studies
CompletedNCT00224822

Aripiprazole for metabolic syndrome linked to other antipsychotic medicines

About this titleRead the official source — NCT00224822
Medication studyAges 18–65United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
AlbuquerqueSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMarch 2004
Recruitment status
Completed
Enrollment listed in the registry
27
Sponsor
New Mexico VA Healthcare System
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT00224822
Official title
Show the full official title

The Effects of Aripiprazole on Patients With "Metabolic Syndrome": An Open-Label Trial

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Albuquerque

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New Mexico VA Healthcare System.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies